PlainRecalls
FDA Drug Moderate Class II Terminated

Desmopressin Acetate Injection USP, 4 mcg/mL, 1 mL Preserved Vial (NDC 0703-5051-01), packaged in 10X1 mL Vials per Tray (NDC 0703-5051-03), Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454.

Reported: March 3, 2021 Initiated: February 10, 2021 #D-0272-2021

Product Description

Desmopressin Acetate Injection USP, 4 mcg/mL, 1 mL Preserved Vial (NDC 0703-5051-01), packaged in 10X1 mL Vials per Tray (NDC 0703-5051-03), Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454.

Reason for Recall

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
2,577 vials
Distribution
Product was distributed nationwide in the USA and Puerto Rico.
Location
Parsippany, NJ

Frequently Asked Questions

What product was recalled?
Desmopressin Acetate Injection USP, 4 mcg/mL, 1 mL Preserved Vial (NDC 0703-5051-01), packaged in 10X1 mL Vials per Tray (NDC 0703-5051-03), Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454.. Recalled by Teva Pharmaceuticals USA. Units affected: 2,577 vials.
Why was this product recalled?
Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.
Which agency issued this recall?
This recall was issued by the FDA Drug on March 3, 2021. Severity: Moderate. Recall number: D-0272-2021.